Sionna Therapeutics (SION) Other Accumulated Expenses (2025 - 2026)

Sionna Therapeutics (SION) reported Other Accumulated Expenses of $17000.0 for Q1 2026, up 183.33% sequentially from $6000.0 in Q4 2025.

Sionna Therapeutics (SION) Other Accumulated Expenses (2025 - 2026) Analysis & Trends

Sionna Therapeutics (SION) has 2 years of Other Accumulated Expenses data on file, last reported at $17000.0 in Q1 2026.

For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $17000.0; the trailing twelve-month figure through Mar 2026 stood at $17000.0 (changed N/A YoY), and the FY2025 full-year result was $6000.0, changed N/A from the prior year.
Other Accumulated Expenses rose to $17000.0 in Q1 2026, from $6000.0 in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $224000.0 in Q3 2025 to a low of $6000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,561.01 Bn	66,560.72 Bn	-
2	Nanobiotix	1,912.79 Bn	1,912.72 Bn	-
3	Akari Therapeutics	1,045.06 Bn	1,045.06 Bn	-
4	BeOne Medicines	469.79 Bn	465.00 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.95 Bn	115.70 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.05 Bn	61.30 Bn	3.31 Bn
7	Belite Bio	62.62 Bn	62.62 Bn	-
8	Argenx Se	56.18 Bn	50.99 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Sionna Therapeutics	2.07 Bn	2.07 Bn	-

Download Data